A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group study (E1501)

Journal of Thoracic Oncology

Volumn 1, Issue 7, 2006, Pages 673-678

  Masters, Gregory A ^a,h   Li, Sigui ^b   Dowlati, Afshin ^c   Madajewicz, Stefan ^d   Langer, Corey ^e   Schiller, Joan ^f   Johnson, David ^g  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

Carboplatin; Exisulind; Gemcitabine; Non small cell lung cancer; Novel agent; Phase II trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; GEMCITABINE; IND 65 056; SULINDAC SULFONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; SULINDAC;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOXIA; INFECTION; LEUKOPENIA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; LUNG TUMOR; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SULINDAC; SURVIVAL RATE;

EID: 34247869815     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200609000-00012     Document Type: Article

References (28)

1. American Cancer Society. Cancer Prevention and Early Detection Facts and Figures . Atlanta: American Cancer Society, 2005.
2. Ginsberg R, Vokes E, Raben A. Non-small cell lung cancer. In DeVita V, Hellman S, Rogenberg S (Eds.), Cancer: Principles and Practice of Oncology , 5th ed. Philadelphia: Lippincott-Raven;1997:855-911.
3. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194.
4. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004;292:470-484.
5. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 2002.
6. Lilenbaum RC, Herndon 2nd, JE List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2006;23:190-196.
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
8. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
9. Carmichael J, Allerheiligen S, Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 1996;23(5 Suppl 10):55-59.
10. Carrato A, Alberola V, Masull B, Galan A, Sanchez J, Garcia-Gomez J. Combination of gemcitabine (gem) and carboplatin as first line treatment in non-small cell lung cancer (NSCLC). Ann Oncol 1998;6(Suppl 4):431P (Abstract).
11. Masters , et al. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol in press.
12. Carrato A, Garcia-Gomez J, Alberola V, et al. Carboplatin (CARBO) in combination with gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). Comparison of two consecutive Phase II trials using different schedules. Proc Am Soc Clin Oncol 1999:1922 (Abstract).
13. Argiris A, Liptay M, LaCombe M, et al. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer 2004;45:243-253.
14. Iaffaioli RV, Tortoriello A, Facchini G, et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999;17:921-926.
15. Haanen C. Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drug 2:677-683.
16. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves GMP-phosphodiesterase inhibition, protein dinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-3342.
17. Hoang T, Kim K, Merchant JJ, et al. A phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;24 (Abstract 7103).
18. Therasse P, Arbuck S, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Am J Clin Oncol 2004;22:330-353.
21. Masotti A, Zannini G, Gentile A, Morandini G. Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 2002;36:99-103.
22. Edelman MJ. Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer. Lung Cancer 2002;38(Suppl 2):S37-S43.
23. Argiris A, Masters G. Carboplatin/gemcitabine for advanced non-small lung cancer: an emerging standard platinum doublet. Cancer Conference Highlights 2003;7:5-8.
24. Kortsik C, Albrecht P, Elmer A. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study. Lung Cancer 2003;40:85-90.
25. Danson S, Clemons M, Middleton M, et al. A randomized study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:322a (Abstract).
26. Herbst RS, Giaccone G, Schiller JH, et al Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
27. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2006;23:5892-5899.
28. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an ECOG trial; E4599. Proc Am Soc Clin Oncol 2006;23 :2s (Abstract).